What Is OSA in Medical Terms? Causes and Treatment

Obstructive sleep apnoea (OSA) in medical terms refers to a common condition in which the upper airway repeatedly collapses during sleep, causing breathing to pause temporarily. These pauses fragment sleep and reduce oxygen levels throughout the body, leading to symptoms such as loud snoring, excessive daytime sleepiness and poor concentration. OSA is classified by severity using the apnoea-hypopnoea index (AHI) and is associated with serious long-term health risks if left untreated. This article explains what OSA means clinically, who is at risk, how it is diagnosed and treated on the NHS, and what happens if it goes unmanaged.

What does OSA mean in medical terms?

OSA stands for obstructive sleep apnoea, a condition in which the upper airway collapses repeatedly during sleep, causing breathing pauses of at least ten seconds that reduce oxygen levels and disrupt sleep.

OSA stands for obstructive sleep apnoea, a common but often underdiagnosed condition in which the upper airway repeatedly collapses during sleep, causing breathing to stop temporarily. The word 'apnoea' comes from the Greek for 'without breath', and in clinical practice an apnoea is defined as a pause in breathing lasting at least ten seconds, in line with American Academy of Sleep Medicine (AASM) scoring criteria.^[5] These pauses can occur many times each night, fragmenting sleep and reducing the amount of oxygen reaching the body's tissues.

The obstruction typically occurs at the level of the soft palate, tongue or throat muscles. During sleep, the muscles that normally keep the airway open relax, and in people with OSA this relaxation is sufficient to cause a partial or complete blockage. The brain detects the drop in oxygen and briefly rouses the person to restore normal breathing, usually without them being aware of it.

OSA is classified by severity using the apnoea-hypopnoea index (AHI), which counts the average number of breathing interruptions per hour of sleep. Based on AASM criteria, mild OSA is generally defined as an AHI of 5 to 14 events per hour, moderate as 15 to 29, and severe as 30 or more. These thresholds guide clinical decision-making and help determine which treatments are most appropriate. It is worth noting that many UK home sleep studies report the oxygen desaturation index (ODI) rather than AHI; ODI measures drops in blood oxygen of 3 or 4 per cent per hour and is used alongside clinical symptoms to guide diagnosis and severity grading in ambulatory settings.^[6][15]

OSA is distinct from central sleep apnoea, in which the brain fails to send the correct signals to the breathing muscles, and from simple snoring, which does not involve significant airway obstruction or oxygen desaturation. Understanding this distinction matters because the management pathways differ considerably.

The NHS provides a patient-facing overview of obstructive sleep apnoea on its website, which is a useful starting point for anyone seeking further information.

What causes obstructive sleep apnoea and who is at risk?

Excess weight is the single most modifiable risk factor for OSA, as adipose tissue around the neck narrows the airway; other risk factors include male sex, older age, alcohol, sedatives and certain anatomical features.

Obstructive sleep apnoea is caused by a combination of anatomical and physiological factors that narrow or destabilise the upper airway during sleep. The most consistently identified risk factor is excess weight: adipose tissue deposited around the neck and throat reduces the diameter of the airway and increases the likelihood of collapse when muscle tone falls during sleep. NHS and NICE guidance both recognise obesity as the single most modifiable risk factor for OSA.

Several other factors increase susceptibility:

• Neck circumference: A collar size above approximately 43 cm (17 inches) in men or 40 cm (16 inches) in women is used as a screening indicator in validated tools such as the STOP-Bang questionnaire.^[7] These figures are screening heuristics rather than diagnostic thresholds.

• Sex: OSA is approximately twice as common in men as in women, though the gap narrows after the menopause.^[13][14]

• Age: Prevalence rises with age as muscle tone in the upper airway naturally decreases.

• Anatomical features: A recessed jaw, enlarged tonsils or adenoids, a deviated nasal septum or a naturally narrow airway can all predispose a person to OSA.

• Alcohol and sedative medicines: Alcohol, opioids and benzodiazepines relax pharyngeal muscles further and can worsen existing OSA or unmask it in susceptible individuals.

• Smoking: Inflammation and fluid retention in the upper airway associated with smoking increase risk.

• Pregnancy: Hormonal changes and weight gain during pregnancy can increase the risk of OSA, particularly in the third trimester.

• Family history: There is a heritable component to both airway anatomy and respiratory control.

Certain medical conditions are also linked to OSA, including hypothyroidism, acromegaly and polycystic ovary syndrome. People with type 2 diabetes have a higher prevalence of OSA than the general population, and research suggests the relationship between the two conditions is bidirectional.^[8][9] Identifying and addressing modifiable risk factors is a central part of long-term management.

How do doctors diagnose OSA in the UK?

UK diagnosis begins with clinical assessment and validated questionnaires such as STOP-Bang and the Epworth Sleepiness Scale, followed by a home sleep study reporting the oxygen desaturation index (ODI), or polysomnography if needed.

Doctors in the UK diagnose OSA through a combination of clinical assessment and sleep studies, following pathways broadly aligned with NICE and British Thoracic Society (BTS) guidance. The process typically begins with a GP consultation, during which the clinician takes a detailed history of symptoms such as loud snoring, witnessed apnoeas, excessive daytime sleepiness, morning headaches and difficulty concentrating. Validated questionnaires are commonly used to support referral decisions: the Epworth Sleepiness Scale quantifies daytime sleepiness, and the STOP-Bang questionnaire (which incorporates snoring, tiredness, observed apnoeas, blood pressure, BMI, age, neck circumference and sex) is widely used in both primary and secondary care to stratify risk.

If OSA is suspected, the GP will usually refer the patient to a specialist sleep service or respiratory clinic. In many NHS trusts, the initial investigation is a home sleep study, also called ambulatory polygraphy or limited channel sleep testing. The patient wears a portable device overnight that records airflow, oxygen saturation, heart rate and chest movement. Results are commonly reported as the oxygen desaturation index (ODI) rather than AHI in ambulatory studies; clinicians interpret these findings alongside symptoms and daytime functioning. This approach is cost-effective and avoids the need for an overnight hospital stay in most cases.

Where the home study is inconclusive, or where a more complex sleep disorder is suspected, a full in-laboratory polysomnography (PSG) may be arranged. PSG records a wider range of physiological signals, including brain activity (EEG), eye movements and limb movements, allowing clinicians to characterise sleep architecture in detail.

The results are interpreted alongside the clinical picture. A diagnosis of OSA is not made on AHI or ODI alone; symptoms and their impact on daily functioning are equally important.

Driving and DVLA obligations: Patients with OSA who experience excessive daytime sleepiness must not drive until their sleepiness is adequately controlled. DVLA guidance requires patients to tell the DVLA if they have a condition causing excessive daytime sleepiness. Group 2 licence holders (bus and lorry drivers) are subject to stricter standards and must meet specific criteria before driving can resume. Clinicians are required to advise patients of these obligations, and patients can find full details on the DVLA's 'Assessing fitness to drive' guidance on GOV.UK.

What treatment options are available on the NHS?

CPAP therapy is the NICE-recommended first-line treatment for moderate to severe OSA; mandibular advancement devices are an alternative for mild to moderate cases, and lifestyle changes such as weight loss support all treatment approaches.

The NHS offers several evidence-based treatments for OSA, with the choice depending on severity, symptoms and individual patient factors. For moderate to severe OSA, continuous positive airway pressure (CPAP) therapy is the first-line treatment recommended by NICE (NICE Technology Appraisal TA139). CPAP delivers a constant stream of pressurised air through a mask worn during sleep, acting as a pneumatic splint to keep the upper airway open. NICE also recommends considering CPAP for people with mild OSA where symptoms significantly affect quality of life.^[3] When used consistently, CPAP is highly effective at eliminating apnoeas, improving sleep quality and reducing daytime sleepiness.

For patients with mild to moderate OSA who cannot tolerate CPAP, or who prefer an alternative, a mandibular advancement device (MAD) may be recommended. These custom-fitted oral appliances hold the lower jaw slightly forward during sleep, increasing the space behind the tongue and reducing the tendency for the airway to collapse. MADs should be custom-fitted and monitored by a trained dental or clinical provider; over-the-counter devices are not equivalent and are not recommended as a substitute. NHS provision of MADs varies by Integrated Care Board (ICB), and local commissioning decisions and eligibility criteria determine availability in different areas.

Lifestyle modification is an important component of management for all patients:

• Weight loss: Even modest reductions in body weight can significantly reduce AHI and symptom burden. Patients can speak to their GP about NHS weight management pathways and referral options.

• Alcohol reduction: Avoiding alcohol, particularly in the evening, reduces pharyngeal muscle relaxation.

• Positional therapy: Some patients have predominantly positional OSA, occurring mainly when sleeping on their back; positional aids can help in this subgroup but are unlikely to benefit those with non-positional OSA.

• Smoking cessation: Supported by NHS Stop Smoking Services.

Surgical options, such as tonsillectomy or procedures to address specific anatomical abnormalities, are considered in selected cases, particularly in children with OSA related to enlarged tonsils. Patients seeking information about weight management as part of their OSA care can speak to their GP, who can advise on NHS pathways and referral options.

What are the health risks if OSA is left untreated?

Untreated OSA is associated with hypertension, coronary artery disease, stroke, worsening type 2 diabetes and excessive daytime sleepiness that significantly raises the risk of road traffic accidents.

Untreated obstructive sleep apnoea carries significant long-term health risks that extend well beyond poor sleep quality. The repeated cycles of oxygen desaturation and arousal place sustained physiological stress on the cardiovascular system, and evidence from systematic reviews and meta-analyses associates untreated OSA with an increased risk of hypertension, coronary artery disease, heart failure and stroke.^[1][3] NICE acknowledges this cardiovascular burden in its guidance on the condition. These findings reflect associations observed in research; the extent to which OSA directly causes these outcomes, rather than sharing common risk factors, continues to be studied.

The relationship between OSA and metabolic health is also well established. Untreated OSA is associated with worsening insulin resistance and poorer glycaemic control in people with type 2 diabetes, and some evidence suggests it may contribute to the development of type 2 diabetes in susceptible individuals.^[8][10] The mechanisms are thought to involve intermittent hypoxia, sympathetic nervous system activation and disruption of hormones that regulate appetite and metabolism, including leptin and ghrelin.^[10]

Daytime consequences of untreated OSA are clinically important in their own right:

• Excessive daytime sleepiness impairs concentration, memory and mood, and is associated with an increased risk of road traffic accidents.^[2][4] Patients who are excessively sleepy must not drive and should follow DVLA guidance on notifying the licensing authority.

• Cognitive impairment can affect work performance and quality of life.

• Depression and anxiety are more prevalent in people with untreated OSA.

There is also evidence of an association between severe untreated OSA and an increased risk of cardiac arrhythmias, including atrial fibrillation.

Patients who experience symptoms suggestive of OSA, particularly witnessed apnoeas, severe daytime sleepiness or new cardiovascular symptoms, should contact their GP for assessment. Those who develop sudden chest pain, severe breathlessness or signs of stroke should call 999 immediately. Prompt diagnosis and treatment substantially reduce the risk of these complications and can meaningfully improve quality of life.

Scientific References

1. Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in adults (NG202) — methods supplement.
2. Sleep apnoea.
3. Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139).
4. Excessive sleepiness and driving.
5. Rules for scoring respiratory events in sleep (Berry RB et al.).
6. Night-to-night variation of the oxygen desaturation index in obstructive sleep apnoea (Fietze I et al.).
7. The discriminative power of STOP-Bang as a screening tool for obstructive sleep apnoea (Mou J et al.).
8. Obstructive sleep apnoea and type 2 diabetes mellitus (Aurora RN et al.).
9. Association between obstructive sleep apnea syndrome and type 1/type 2 diabetes mellitus: A systematic review and meta-analysis.
10. Obstructive sleep apnea and type 2 diabetes: is there a link? (Pamidi S et al.).
11. Impact of CPAP Therapy Adherence on Time to First Recurrence of Paroxysmal Atrial Fibrillation in Patients with Severe Obstructive Sleep Apnea.
12. Cardiac Rhythm Disorders in Patients with Obstructive Sleep Apnea. Annals of African Medicine.
13. Roles of gender, age, race/ethnicity, and residential socioeconomics in obstructive sleep apnea syndromes. Current Opinion in Pulmonary Medicine.
14. Expert consensus on the diagnosis and treatment of obstructive sleep apnea in women. Chinese Journal of Tuberculosis and Respiratory Diseases.
15. Modified scoring criteria to improve the accuracy of the home sleep apnea test. Sleep & Breathing.
16. Severity classification of obstructive sleep apnea using AASM and SEPAR criteria: A cross-sectional reclassification analysis. European Archives of Oto-Rhino-Laryngology.

Frequently Asked Questions